AAV-PRO问卷与ANCA相关性血管炎既定结局指标的关联
前瞻性纵向研究纳入156例ANCA相关性血管炎患者,在基线和3-6个月后完成AAV-PRO、BDI、SF-36、BVAS和VDI。AAV-PRO各域与BDI及SF-36各亚域强相关,但与临床医生衍生的BVAS和VDI不相关,作者认为AAV-PRO可作为补充传统终点的有价值结局测量工具。
要点
- AAV-PRO各域评分与BDI及SF-36全部八个亚域强相关(所有r≥0.319及|r|≥0.267,所有P≤0.001)。
- AAV-PRO各域评分与临床医生衍生的BVAS和VDI不相关。
- 作者认为AAV-PRO问卷可作为临床试验中补充传统终点的有价值结局测量工具。
核心结论
- 研究数据显示AAV-PRO所有子域与既定问卷BDI和SF-36具有聚合效度。
- AAV-PRO各域评分与临床医生衍生的工具(包括BVAS和VDI)不相关。
- 作者认为AAV-PRO问卷可作为结局的有价值测量工具,可能补充临床试验中的传统终点。
研究设计与样本
- 前瞻性纵向研究,在基线(t1)和3-6个月后(t2)完成AAV-PRO、贝克抑郁量表(BDI)、健康调查简表36(SF-36)、伯明翰血管炎活动评分(BVAS)和血管炎损伤指数(VDI)。
- 共纳入156例ANCA相关性血管炎(AAV)患者,记录包括诊断、治疗、复发和器官表现在内的患者数据。
- 数据采用t检验和基于相关性的回归分析。
主要发现
- 入组时平均BVAS为1.4 ± 3.74。
- 报告「活动性疾病」的患者AAV-PRO各域评分中位数高于报告「缓解」的患者(P < 0.001)。
- 相关性分析中,所有AAV-PRO域评分与BDI强相关(所有r ≥ 0.319,所有P ≤ 0.001),并与SF-36全部八个亚域相关(所有|r|≥0.267,所有P ≤ 0.001)。
- 回归分析显示AAV-PRO各域由BDI和SF-36域强预测(各域最强预测因子的|β| ≥ 0.240)。
- 纵向比较(t1/t2)中总体结果无显著变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The ANCA-associated vasculitis (AAV) patient-reported outcome (AAV-PRO) questionnaire was developed to capture the impact of AAV and its treatment. We investigated the association of specific AAV-PRO domains with disease activity and extent, damage, depression, health-related quality of life, and treatment. METHODS: In a prospective longitudinal study, AAV-PRO, Beck's depression inventory (BDI), Short Form 36 (SF-36), BVAS and Vasculitis Damage Index (VDI) were completed at baseline (t1) and after 3-6 months (t2). In addition, patient data (including diagnosis, therapies, relapses, and organ manifestations) were recorded. Data were analysed by t-tests and correlation-based regression analyses. RESULTS: A total of 156 patients with AAV participated. The mean BVAS at the time of enrolment was 1.4 ± 3.74. The median AAV-PRO domain scores were higher in patients reporting 'active disease' compared with those reporting 'in remission' (P < 0.001). In the correlation analyses, all AAV-PRO domain scores correlated strongly with the BDI (all r ≥ 0.319, all P ≤ 0.001) as well as with all eight SF-36 subdomains (all |r|≥0.267, all P ≤ 0.001). The regression analyses showed that AAV-PRO domains were strongly predicted by the BDI and SF-36 domains (|β| ≥ 0.240 for the strongest predictor of each domain). In the longitudinal comparison (t1/t2), there were no significant changes in the overall results. CONCLUSION: Our data show convergent validity for all AAV-PRO subdomains, using the established questionnaires BDI and SF-36. The AAV-PRO domains scores were not correlated with clinician-derived instruments (including the BVAS and the VDI). Thus, we regard the AAV-PRO questionnaire as a valuable measure of outcomes that might complement traditional end-points in clinical trials.
引用
- Maunz A, Jacoby J, Henes J, et al. Association of the AAV-PRO questionnaire with established outcome measures in AAV. Rheumatology (Oxford). 2024. PMID: 37129542. doi:10.1093/rheumatology/kead199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。